<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00428077</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000526322</org_study_id>
    <secondary_id>OHSU-HEM-05053-L</secondary_id>
    <secondary_id>OHSU-1358</secondary_id>
    <nct_id>NCT00428077</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia</brief_title>
  <official_title>A Multi-Center Pilot Phase II Trial of a Synthetic Tumor-Specific Breakpoint Peptide Vaccine in Patients With Chronic Myeloid Leukemia (CML) and Minimal Residual Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OHSU Knight Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>OHSU Knight Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from a peptide may help the body build an effective immune response
      to kill cancer cells.

      PURPOSE: This phase II trial is studying how well vaccine therapy works in treating patients
      with chronic phase chronic myelogenous leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the antileukemic effects of tumor-specific Breakpoint Cluster Region-Abelson
           Murine Leukemia(BCR-ABL) junction specific peptide vaccine, as measured by a decrease in
           circulating BCR-ABL transcripts by reverse-transcriptase polymerase chain reaction
           (RT-PCR), that persist for at least 3 months, in patients with chronic phase chronic
           myelogenous leukemia.

        -  Determine the percentage of patients treated with this vaccine who become
           RT-PCR-negative for BCR-ABL transcripts.

        -  Compare response in patients with B3A2 junctions vs B2A2 junctions when treated with
           this vaccine.

        -  Determine the immunologic response over 1 year in patients treated with this vaccine.

        -  Correlate response with specific HLA types in these patients.

        -  Determine the safety of this vaccine in these patients.

      OUTLINE: This is a pilot, multicenter study.

      Patients receive BCR-ABL junction-specific peptide vaccine subcutaneously in weeks 2, 4, 6,
      8, and 11 and then once monthly for 10 months.

      BCR-ABL transcript levels are assessed by quantitative reverse-transcriptase polymerase chain
      reaction at baseline, weeks 2, 4, and 6, every 3 months during treatment, and then 2 weeks
      after completion of study treatment.

      PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Withdrawn because there were no dramatic changes in the main endpoint, as well as low
    enrollment numbers. The data are not interpretable in terms of efficacy.
  </why_stopped>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With One-log Decrease in Circulation Breakpoint Cluster Region-Abelson Murine Leukemia(BCR-ABL) Transcripts That Persists for at Least Three Months During the 1-year Treatment Period.</measure>
    <time_frame>Every 3 months for the duration of the 1-year treatment period. .</time_frame>
    <description>One-log decrease in circulating BCR-ABL transcripts (RT-PCR) that persists for at least three months during the 1-year treatment period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Patients Who Become RT-PCR-negative for BCR-ABL Transcripts</measure>
    <time_frame>12-24 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of Response in Patients With B3A2 Junctions vs B2A2 Junctions</measure>
    <time_frame>12-24 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunologic Response Over 1 Year</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation of Response With Specific HLA Types</measure>
    <time_frame>12-24 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of a Vaccine Containing Native and Synthetic Chronic Myeloid Leukemia (CML) Peptides Over 1 Year Treatment.</measure>
    <time_frame>Weeks 2, 4, 6, 9, and monthly thereafter up to 2 years.</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">4</enrollment>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bcr-abl peptide vaccine</intervention_name>
    <description>Patients will be vaccinated 15 times over 12 months with a vaccine comprised of native and synthetic break-point cluster region-Abelson murine leukemia(BCR-ABL) specific peptides and the immunologic adjuvants, Montanide ISA 51-VG.</description>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>reverse transcriptase-polymerase chain reaction</intervention_name>
    <description>A &quot;baseline&quot; reverse transcriptase-polymerase chain reaction(RT-PCR) transcript level of BCR-ABL will be determined after enrollment on study. This baseline will be used to measure response to the vaccine. Patients will have 3 quantitative RT-PCR tests for BCR-ABL transcript levels performed on their peripheral blood in the first month after enrolling on study. Peripheral blood samples will be drawn at approximately 1-month prior (about day -30), 2 weeks prior (about day -14), and the day of the first vaccination (day 0). Samples will be analyzed at a central lab and the three values will be averaged to determine a &quot;baseline&quot; circulating transcript level. During this one-month period, a peripheral blood sample will be analyzed to determine whether patients have a B3A2 or B2A2 junction.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of Philadelphia chromosome-positive or BCR-ABL-positive chronic phase
             chronic myelogenous leukemia (CML)

               -  In complete cytogenetic remission confirmed by 2 bone marrows ≥ 1 month apart

               -  Minimal residual disease

          -  Detectable BCR-ABL transcript levels obtained &lt; 6 months apart AND ≤ 0.5-log lower
             than the lowest value obtained within the past 6 months

        PATIENT CHARACTERISTICS:

          -  Karnofsky performance status 80-100%

          -  Bilirubin &lt; 2 times upper limit of normal (ULN)

          -  Creatinine &lt; 1.5 times ULN

          -  ALT and AST &lt; 2.5 times ULN

        PRIOR CONCURRENT THERAPY:

          -  Recovered from prior therapy

          -  No major surgery within the past 4 weeks

          -  No prior chemotherapy

          -  No prior immunosuppressive therapy

          -  No prior corticosteroids

          -  No prior stem cell transplantation

          -  No radiotherapy within the past 4 weeks

          -  No other concurrent investigational agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Deininger, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>OHSU Knight Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>OHSU Knight Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2007</study_first_submitted>
  <study_first_submitted_qc>January 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2007</study_first_posted>
  <results_first_submitted>May 26, 2011</results_first_submitted>
  <results_first_submitted_qc>August 1, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 31, 2011</results_first_posted>
  <last_update_submitted>August 31, 2011</last_update_submitted>
  <last_update_submitted_qc>August 31, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruited from patient database in medical clinic.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Breakpoint Cluster Region-Abelson Murine Leukemia(BCR-ABL)</title>
          <description>Patients will be vaccinated 15 times over 12 months with a vaccine comprised of native and synthetic BCR-ABL (break-point cluster region-Abelson murine leukemia) specific peptides and the immunologic adjuvants, Montanide ISA 51-VG.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Breakpoint Cluster Region-Abelson Murine Leukemia(BCR-ABL)</title>
          <description>Patients will be vaccinated 15 times over 12 months with a vaccine comprised of native and synthetic BCR-ABL (break-point cluster region-Abelson murine leukemia) specific peptides and the immunologic adjuvants, Montanide ISA 51-VG.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.75" spread="3.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With One-log Decrease in Circulation Breakpoint Cluster Region-Abelson Murine Leukemia(BCR-ABL) Transcripts That Persists for at Least Three Months During the 1-year Treatment Period.</title>
        <description>One-log decrease in circulating BCR-ABL transcripts (RT-PCR) that persists for at least three months during the 1-year treatment period.</description>
        <time_frame>Every 3 months for the duration of the 1-year treatment period. .</time_frame>
        <population>Per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Breakpoint Cluster Region-Abelson Murine Leukemia(BCR-ABL)</title>
            <description>Patients with Philadelphia Chromosome (Ph+) or Breakpoint Cluster Region-Abelson Murine Leukemia(BCR-ABL),positive Chronic Myeloid Leukemia(CML), in cytogenetic remission, with minimal residual disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With One-log Decrease in Circulation Breakpoint Cluster Region-Abelson Murine Leukemia(BCR-ABL) Transcripts That Persists for at Least Three Months During the 1-year Treatment Period.</title>
          <description>One-log decrease in circulating BCR-ABL transcripts (RT-PCR) that persists for at least three months during the 1-year treatment period.</description>
          <population>Per protocol.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="10" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients Who Become RT-PCR-negative for BCR-ABL Transcripts</title>
        <time_frame>12-24 Months</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Comparison of Response in Patients With B3A2 Junctions vs B2A2 Junctions</title>
        <time_frame>12-24 Months</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Immunologic Response Over 1 Year</title>
        <time_frame>12 months</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Correlation of Response With Specific HLA Types</title>
        <time_frame>12-24 Months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety of a Vaccine Containing Native and Synthetic Chronic Myeloid Leukemia (CML) Peptides Over 1 Year Treatment.</title>
        <time_frame>Weeks 2, 4, 6, 9, and monthly thereafter up to 2 years.</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were measured during entire 12 month period subjects received study drug.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Breakpoint Cluster Region-Abelson Murine Leukemia(BCR-ABL)</title>
          <description>Patients will be vaccinated 15 times over 12 months with a vaccine comprised of native and synthetic BCR-ABL (break-point cluster region-Abelson murine leukemia) specific peptides and the immunologic adjuvants, Montanide ISA 51-VG.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Viral Gastroenteritis</sub_title>
                <description>In one patient a grade 3 GI AE (acute gastroenteritis) occurred and led to hospitalization. This event was felt to be unrelated to study drug.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataracts</sub_title>
                <description>One patient was diagnosed with grade 2 cataracts while on study. Given that this is common in the patient's age group, it is unlikely to be related to study medication.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Patients experienced grade 1-2 fatigue in association with the injection of GM-CSF. This is an established side effect of the agent.</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site induration</sub_title>
                <description>All patients developed grade 1-2 injections site indurations, which slowly resolved over several months.</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael Deininger, MD, PhD</name_or_title>
      <organization>University of Utah Huntsman Cancer Institute</organization>
      <phone>801-585-3229</phone>
      <email>michael.deininger@hci.utah.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

